DNMT1 and pachyonychia congenita: For example, NCT04257448 aims to determine the safety and tolerability of HDAC inhibition by romidepsin and DNMT inhibition by azacitidine or both agents, in combination with gemcitabine/nab-paclitaxel in patients with advanced PC.